Core Insights - Merck is deepening its collaboration with Chinese pharmaceutical companies, exemplified by a nearly $2 billion deal with Hengrui Medicine for exclusive rights to a drug outside of China [1][2] - The partnership with Hengrui Medicine involves HRS-5346, an oral small molecule Lp(a) inhibitor currently in Phase II clinical trials in China, which aims to address cardiovascular disease risk factors [2][4] - Merck's collaborations with local companies reflect the growing innovation capabilities of China's pharmaceutical industry, with a notable increase in drug development pipelines [3][5] Group 1 - Merck has established a significant presence in China over the past 30 years, with global revenues exceeding $64 billion, and is actively expanding its market influence through local partnerships [1][4] - The collaboration with Hengrui Medicine is part of a broader trend, as Merck has also signed a global exclusive licensing agreement with Hansoh Pharmaceutical for HS-10535, another investigational drug [3][6] - The Chinese pharmaceutical market has seen rapid growth, with a 15.1% increase in drug pipelines, positioning China as the second-largest pharmaceutical R&D market globally [5][6] Group 2 - Merck's China R&D Center, established in 2011, is one of the largest among multinational pharmaceutical companies in China, supporting both local and global operations [7] - The company has a "three-pronged" business model in China, encompassing R&D, manufacturing, and commercial operations, with factories in Hangzhou, Ningbo, and Tianjin [8] - Merck plans to introduce over 40 new products and indications to the Chinese market in the next five years, reflecting its commitment to meeting local healthcare needs [8][9]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing significant growth, with leading stocks such as Sangfor and CSPC Pharmaceutical rising over 6% and 8% respectively, driven by positive market sentiment and key developments in the industry [1][2]. Group 1: Market Performance - The Hong Kong innovative drug ETF (520880) opened high and increased by over 3%, with more than 70% of its portfolio invested in leading innovative drug stocks [1]. - Sangfor Pharmaceutical and CSPC Pharmaceutical both saw their stock prices increase significantly, indicating strong market performance in the innovative drug sector [1][2]. Group 2: Industry Developments - Sangfor Pharmaceutical plans to spin off its minoxidil brand, Mandi International, for a listing on the Hong Kong Stock Exchange [1]. - CSPC Pharmaceutical received approval for clinical trials of its ActRIIA/B antibody JMT206 injection, aimed at treating obesity [1]. Group 3: ETF Insights - The fund manager of the Hong Kong innovative drug ETF highlighted that the innovative drug sector is seeing continuous catalysts, with significant business development transactions exceeding $1 billion this year [2]. - The ETF is positioned to benefit from upcoming industry conferences and the expected release of innovative drug insurance negotiations results in December [2]. - The index tracked by the ETF has a high concentration of leading stocks, with the top ten holdings accounting for over 71% of the index weight, providing a strong representation of the innovative drug sector [3].

来源：新浪基金∞工作室 港股创新药ETF（159567）现任基金经理为马君。马君自2024年1月3日管理（或拟管理）该基金，任职 期内收益68.04%。 最新定期报告显示，港股创新药ETF（159567）重仓股包括百济神州、康方生物、信达生物、中国生物 制药、中国生物制药、石药集团、三生制药、翰森制药、科伦博泰生物-B、再鼎医药，持仓占比如下。 股票代码股票名称持仓占比持仓股数（股）持仓市值（元）06160百济神州10.62%436.35万8.17亿09926 康方生物10.55%630.20万8.12亿01801信达生物10.21%893.55万7.86亿01177中国生物制药9.62%9966.80万 7.41亿08027中国生物制药9.62%9966.80万7.41亿01093石药集团7.56%6809.40万5.83亿01530三生制药 7.25%2038.75万5.58亿03692翰森制药5.39%1260.00万4.15亿06990科伦博泰生物-B3.48%57.08万2.68亿 09688再鼎医药2.73%862.34万2.10亿 港股创新药ETF（159567）成立于2024年1月3日，基金全 ...

Market Overview - The Hong Kong stock market showed a significant recovery on November 24, with all three major indices ending a streak of declines[9] - Large tech stocks performed strongly, with Kuaishou rising over 7%, and NetEase and Bilibili increasing over 5%[9] - The Hang Seng Tech Index closed at 5,546, up 2.78% for the day and 24.11% year-to-date[3] Sector Performance - Innovative pharmaceuticals and outsourcing concepts saw notable gains, with companies like Innovent Biologics rising over 6%[9] - Military stocks also performed well, with China Shipbuilding Defense up over 13%[9] - Oil stocks were weak, with China National Offshore Oil Corporation and China Oilfield Services both declining over 1%[9] U.S. Market Insights - On the same day, U.S. markets saw all three major indices close higher, driven by increased bets on a Federal Reserve rate cut[9] - The "Magnificent Seven" tech stocks, including Google and Nvidia, all rose, with Google gaining over 6%[9] - The S&P 500 index is projected to achieve double-digit annual growth according to HSBC strategists[14] Economic Indicators - The Federal Reserve is expected to cut rates in December, with market predictions showing a 70% probability[14] - The U.S. economy's third-quarter GDP report has been delayed due to a government shutdown, affecting economic analysis[14] Investment Trends - The Nasdaq Golden Dragon China Index rose by 2.82%, indicating a positive trend for Chinese concept stocks[13] - Significant inflows into semiconductor stocks were noted, with companies like Broadcom surging 11%[13]

Investment Rating - The industry investment rating is "Outperform the Market" [29] Core Insights - AbbVie reported a total revenue of $44.542 billion for the first three quarters of 2025, representing an 8.0% year-over-year growth, with Q3 revenue reaching $15.776 billion, up 9.1% [5][9] - The strong performance is primarily driven by two key immunology drugs, Rinvoq and Skyrizi, which have seen significant sales growth [5][19] - AbbVie has raised its full-year guidance, indicating positive momentum across its business segments, including immunology, neuroscience, and oncology [5][9] Summary by Sections Part 1: Financial Overview and Key Events - AbbVie’s revenue contributions from major segments include Immunology at $21.780 billion (+12.3%), Neuroscience at $7.806 billion (+20.3%), and Oncology at $4.991 billion (+2.6%) for the first three quarters of 2025 [5][9] - The company has advanced several projects into regulatory approval and submission phases, including Rinvoq for various indications [10][12][23] Part 2: Core Product Sales Analysis - Rinvoq generated $5.930 billion in revenue for the first three quarters of 2025, a 43.3% increase, while Skyrizi achieved $12.556 billion, growing 58.1% [19][17] - The combined sales of Rinvoq and Skyrizi reached $6.9 billion in Q3 alone, establishing them as leading products in the immunology sector [19][27] Part 3: Future Pipeline Milestones - In 2026, AbbVie anticipates five drug approvals, four regulatory submissions, and five Phase III data readouts, including Rinvoq for vitiligo and alopecia areata [22][23] - Key upcoming regulatory events include submissions for Tavapadon for Parkinson's disease and Venclexta for higher-risk MDS [22][23] Part 4: Investment Recommendations - The strong sales of Skyrizi and Rinvoq are expected to continue driving AbbVie's growth, with Skyrizi projected to become a "super blockbuster" in 2024 [27] - Investors are advised to monitor domestic companies targeting the IL-23 pathway, such as Innovent Biologics and Kintor Pharmaceutical [27]

Group 1: Market Overview - The US stock market saw all three major indices rise, with the Dow Jones up 0.44%, S&P 500 increasing by 1.5%, and Nasdaq gaining 2.69% [4] - The Hong Kong stock market also performed well, with the Hang Seng Index rising by 1.97% and the Hang Seng Tech Index up 2.78%, driven by strong performances in technology and automotive stocks [5] - A-shares in China experienced a collective increase, with the Shanghai Composite Index up 0.05%, Shenzhen Component Index up 0.37%, and ChiNext Index up 0.31%, despite a decrease in trading volume [6] Group 2: Commodity Prices - Gold prices rose significantly, closing at $4,134.79 per ounce, up 1.69%, while silver increased by 2.64% to $51.36 per ounce [7] - Crude oil prices also saw gains, with WTI crude closing at $58.89 per barrel, up 1.67%, and Brent crude at $62.79 per barrel, up 1.39% [7] Group 3: Economic Indicators - The Federal Reserve officials expressed support for a potential interest rate cut in December, with probabilities rising to 80% for a rate decrease [11] - The Chinese central bank announced a 10,000 billion yuan MLF operation scheduled for November 25, indicating ongoing monetary policy support [13]

【导读】港股三大指数大涨，AI概念股集体上攻 首先，千问App的底层技术支撑是阿里通义千问（Qwen）大模型。据了解，Qwen系列模型自2023年起便通过开源策略，在全球技术社区积累了广泛影响 力，累计下载量已突破6亿次，其性能也获得了包括英伟达CEO黄仁勋等的公开认可。其次，千问App精准定位为"会聊天能办事的个人AI助手"，强调其 实用价值。 创新药涨幅居前 11月24日，创新药概念股涨幅居前，三生制药涨6.07%，恒瑞医药涨5.61%，翰森制药涨5.29%，药明康德涨5.12%。 中国银河证券表示，看好2026年医药行业投资机会，近期震荡调整后估值已回落至相对低位，有望在2026年重启升势。投资思路上，寻找医药硬科技和细 分赛道超额收益。推荐关注创新药、创新器械（影像、高值耗材、消费器械等）、医疗AI等方向，关注医药消费复苏及独立第三方临床实验室（ICL）等 方向。 11月24日，港股三大指数集体大涨。截至收盘，恒生指数涨1.97%，报收于25716.50点；恒生国企指数涨1.79%，报收于9079.42点；恒生科技指数涨 2.78%，报收于5545.56点。全日大市成交额为3026亿港元，南向资金净买 ...

Market Overview - The Hong Kong stock market experienced a significant rise, with the Hang Seng Index increasing by 1.97% to close at 25,716.50 points, the Hang Seng China Enterprises Index rising by 1.79% to 9,079.42 points, and the Hang Seng Tech Index climbing by 2.78% to 5,545.56 points. The total market turnover reached 302.6 billion HKD, with net inflows from southbound funds amounting to 8.571 billion HKD [2][3]. AI Sector Performance - AI concept stocks saw a collective surge, with notable increases in share prices: Kuaishou-W rose by 7.11%, NetEase-S by 5.87%, Bilibili-W by 5.67%, Kingsoft Cloud by 4.96%, and Alibaba-W by 4.67% [4][5]. Alibaba's AI Assistant Launch - Alibaba announced that its AI assistant "Qianwen App" achieved over 10 million downloads in its first week of public testing, indicating strong market interest. The app is supported by the Qwen model, which has gained significant traction in the tech community with over 600 million downloads since its launch [6]. Innovative Drug Sector - The innovative drug sector showed strong performance, with notable stock increases: 3SBio rose by 6.07%, Hengrui Medicine by 5.61%, Hansoh Pharmaceutical by 5.29%, and WuXi AppTec by 5.12% [7][8]. Investment Outlook for Pharmaceuticals - China Galaxy Securities expressed optimism about investment opportunities in the pharmaceutical industry by 2026, suggesting that recent market adjustments have led to relatively low valuations. The report recommends focusing on innovative drugs, medical AI, and independent clinical laboratories [9]. Baidu's Rating Upgrade - Baidu's stock increased by 4.19% following a rating upgrade from Morgan Stanley, which raised its investment rating from "Neutral" to "Overweight." The report estimates Baidu's cloud business valuation at approximately 34 billion USD and highlights the potential for valuation reassessment [10][11]. Increased Capital Expenditure in AI - UBS reported that major Chinese internet companies are increasing capital expenditures and focusing more on AI investments. The report emphasizes that these companies are adapting quickly to demand changes and improving GPU efficiency amid geopolitical uncertainties [13].

Investment Rating - The report maintains an "Outperform" rating for several companies including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The report continues to recommend innovative pharmaceuticals and the industry chain, highlighting the high prosperity in innovative drugs and the potential for value re-evaluation [6][26]. - The A-share pharmaceutical sector underperformed the market in the third week of November 2025, with the SW Pharmaceutical and Biological index falling by 6.9% compared to a 3.9% drop in the SHCOMP [9][19]. - The report identifies top gainers and losers in the A-share market, with Hainan Haiyao (+23.8%) and Remed (+13.9%) being the top gainers, while GDK (-25.5%) and Nanjing Hicin Pharmaceutical (-23.2%) were the biggest losers [16][19]. - The premium level of the pharmaceutical sector relative to all A-shares is currently at a normal level, with a relative premium rate of 71.8% as of November 21, 2025 [18][22]. Summary by Sections 1. Continued Recommendation for Innovative Pharmaceuticals and Industry Chain - The report emphasizes the ongoing recommendation for innovative drugs and the industry chain, maintaining "Outperform" ratings for various companies in the pharmaceutical and biotech sectors [6][26]. 2. A-share Pharmaceutical Sector Performance - In the third week of November 2025, the A-share pharmaceutical sector underperformed the broader market, ranking 23rd among Shenwan primary industries [9][19]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index falling by 7.5%, while the U.S. pharmaceutical sector outperformed, with the S&P Healthcare Select Sector rising by 1.8% [19][26].

Core Insights - The pharmaceutical MNC supply chain has extremely high entry barriers, requiring years for supplier certification through cross-departmental audits in technology, quality, EHS, and compliance. Once included in the qualified supplier list, a strong lock-in effect is formed, making it difficult for new entrants to disrupt the existing supply structure even if they meet technical standards, thus demonstrating a strong first-mover advantage [4][7]. - MNCs demand far more than conventional quality compliance, emphasizing full-process controllability and risk management capabilities. Compliance with guidelines such as EU GMP and ICHQ is required, along with the establishment of traceability systems and safety stock. Any process changes or relocation of production sites must undergo strict and time-consuming certification [4][7]. - In procurement decisions, MNCs are relatively insensitive to price factors, prioritizing the integrity of the supply chain over cost. For MNCs, API costs represent only a small portion of their terminal formulation sales, leading them to pay a premium for stable, traceable, and zero major quality incident supply capabilities, viewing supply chain resilience as a core competitive advantage rather than a cost item. Thus, entering the MNC supply chain often means effectively avoiding "price internalization" [4][7]. - Investment recommendations include innovative drug and device companies such as Furuya Co., Aonlikang, Shutaishen, Weichuang Bio, and others. From the perspective of CXO and raw materials, companies like WuXi AppTec, Jiuzhou Pharmaceutical, Chengda Pharmaceutical, and others are suggested for attention [4][7]. Market Performance Overview - As of November 21, 2025, the TTM-PE of the pharmaceutical and biotechnology industry is 48.84 times, which is 100% higher than the historical lowest PE valuation of 24.38 times on January 3, 2019. The premium rate relative to the CSI 300 is 252%, exceeding the historical lowest valuation premium of 124% on February 6, 2018, by 128 percentage points, and is 11 percentage points higher than the average valuation premium rate of 241% over the past decade [8][12]. - From November 17 to November 21, 2025, the pharmaceutical and biotechnology sector experienced a decline of 6.88%, ranking 22nd among 27 sub-industries. The chemical raw materials sector saw the largest decline at -8.60% [12][15]. Industry Dynamics - Pfizer's Class 1 new drug, Matacizumab, was approved for marketing on November 21, 2025, for the routine prevention and treatment of bleeding in patients with severe hemophilia A or B [20]. - Boehringer Ingelheim's Class 1 new drug, BI764198, was proposed for inclusion as a breakthrough therapy on November 18, 2025, targeting primary focal segmental glomerulosclerosis [21]. - The PD-1 inhibitor H drug, Surulutumab, developed by Fuhong Hanlin, was officially included as a breakthrough therapy on November 20, 2025, for gastric cancer treatment [22]. - On November 17, 2025, FDA approved the biosimilar of Tysabri, developed by Sandoz, for multiple sclerosis and Crohn's disease [23].